Quality of Life and Health Costs: The Feasibility of Cost-Utility Analysis in Schizophrenia
Authors:
- 15 June 2016
- book chapter
- Published by Springer Nature
- p. 175-183
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The Impact of Newer Atypical Antipsychotics on Patient-Reported Outcomes in SchizophreniaCNS Drugs, 2013
- Measuring Quality of Life in Patients with SchizophreniaPharmacoEconomics, 2012
- Impact of Atypical Antipsychotics on Quality of Life in Patients with SchizophreniaCNS Drugs, 2004
- Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysisBMJ, 2000
- Economic and Health State Utility Determinations for Schizophrenic Patients Treated With Risperidone or HaloperidolJournal of Clinical Psychopharmacology, 1997
- The Aims of Antipsychotic MedicationCNS Drugs, 1995
- The economic burden of schizophreniaPsychiatric Bulletin, 1990
- Methodology for measuring health-state preferences—III: Population and context effectsJournal of Clinical Epidemiology, 1989
- Methodology for measuring health-state preferences—II: Scaling methodsJournal of Clinical Epidemiology, 1989
- Methodology for measuring health-state preferences—I: Measurement strategiesJournal of Clinical Epidemiology, 1989